Fluicell welcomes Niek Welkenhuysen
Fluicell welcomes Niek Welkenhuysen who started with us in May as a development engineer. Although Niek recently joined…
BioPen Nanoparticle Delivery
We have just released a new application example for BioPen®, covering nanoparticle delivery for single-cell biology. Using Fluicell’s…
10
Jun
2021
Fluicell CEO Newsletter 04, 2021
The announcement of the BioRej™ Advance program for regenerative medicine partnerships in the beginning of May was the…
01
Jun
2021
Fluicell welcomes Sandra Tejedor
Sandra Tejedor, who recently finished her PhD at University of Valencia, now joins Fluicell as an Application Scientist,…
18
May
2021
Fluicell enters into the world of regenerative medicine
Today, Fluicell takes a big step forward in the development of the company. Based on Biopixlar’s unique high-resolution…
07
May
2021
Researchers develop antibodies targeting ion channel hTRPV1, important for pain therapy
In a research article, published on April 16 in Science Advances, researchers from Oblique Therapeutics AB together with…
19
Apr
2021
Årsstämma 2021
English version follows below. Med anledning av den fortsatta smittspridningen av viruset som orsakar covid-19 kommer Fluicells årsstämma…
16
Apr
2021
CEO Newsletter 3, 2021
”Retreading old footsteps has never been a driving force for Fluicell” In the third issue of the CEO…
30
Mar
2021
Fluicell launches Biozone 6
We are launching Biozone 6, Fluicell’s new innovation for single-cell pharmacology that lets you perform drug testing and…
15
Mar
2021